Objective To analyze the regulatory effect of Guanxinning tablets on clopidogrel resist-ance in patients with severe blood stasis syndrome of coronary heart disease after percutaneous coronary intervention(PCI).Methods A total of 94 patients with severe blood stasis syndrome of coronary heart disease who underwent PCI with clopidogrel resistance and were admitted to our hospital between July 2022 and July 2023 were randomly divided into a control group(n=47)and an observation group(n=47)using a random number table method.The control group received aspirin combined with clopidogrel while the observation group was additionally given Guanxinning tablets.The therapeutic effect,hemorheological indicators,platelet inhibition rate,residual platelet fibrin clot strength and adverse reactions in the two groups before and after treatment were observed.Results The effective rate of the observation group was significantly higher than that of the control group(χ2=4.374,P<0.05).After treatment,the observation group showed a significant decrease in whole blood viscosity with high shear and low shear compared to the control group(P<0.05).After treatment,the platelet inhibition rate in the observation group was signifi-cantly higher than in the control group,while the residual platelet fibrin clot strength was significantly lower(P<0.05).The total incidence of adverse reactions in the observation group was lower than in the control group(χ2=3.887,P<0.05).Conclusion Guanxinning tablets can have a positive effect on clopi-dogrel resistance in patients with severe blood stasis syndrome of coronary heart disease after PCI,improve clinical symptoms significantly,and effectively regulate clopidogrel resistance.
NETL
NSTL
万方数据
